Association between VEGF-634G>C Gene Polymorphism with Gastric Premalignant Lesions and Serum VEGF Levels in Helicobacter pylori Gastritis Patients
DOI:
https://doi.org/10.3889/oamjms.2018.266Keywords:
Gastric premalignant lesion, Helicobacter pylori, VEGF, polymorphismAbstract
AIM: To evaluate the association between VEGF-634G>C gene polymorphism with premalignant gastric lesions as well as the level of VEGF.
METHODS: This cross-sectional study included patients with H. pylori gastritis at Haji Adam Malik General Hospital, Permata Bunda General Hospital, and Universitas Sumatera Utara Hospital, Medan, Indonesia. Detection of H. pylori infection was made using positive results of 14C-UBT, rapid urease test, and/or immunohistochemistry. Gastric premalignant lesion diagnosis was made when one or more of the following were present: chronic atrophic gastritis, intestinal metaplasia, or dysplasia. Real-time polymerase chain reaction (RT-PCR) was used to examine VEGF-634G>C gene polymorphism. Additionally, serum samples of patients with H. pylori gastritis were obtained to determine the level of circulating VEGF. Data were analysed using SPSS version 22.
RESULTS: A total number of 87 patients with H. pylori gastritis were included in this study. Of all participants, 26 patients (29.9%) showed gastric premalignancy. There was a significant association between GG+GC genotype of VEGF-634G>C and gastric premalignant lesions (P = 0.003; OR (CI 95%) = 6.07 (1.88-41.71)). VEGF-634 G>C polymorphism also showed an association with VEGF serum levels (P = 0.005). Patients with the GG+GC genotype would be at risk of 3.16 times to have high VEGF levels compared to CC genotypes.
CONCLUSION: VEGF-634G>C polymorphism, in particular, GG+GC genotype was associated with an increased risk of gastric premalignant transformation as well as having high VEGF levels in patients with H.pylori gastritis.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2): 74-108. https://doi.org/10.3322/canjclin.55.2.74 PMid:15761078
Yanaoka K, Oka M, Mukoubayashi C, Yoshimura N, Enomoto S, Iguchi M, et al. Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol Biomarkers Prev. 2008; 17(4):838–45. https://doi.org/10.1158/1055-9965.EPI-07-2762 PMid:18398025
Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer. 2004; 109(1):138-43. https://doi.org/10.1002/ijc.11680 PMid:14735480
Park YH, Kim N. Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer. J Cancer Prev. 2015; 20(1):25-40. https://doi.org/10.15430/JCP.2015.20.1.25 PMid:25853101 PMCid:PMC4384712
Zullo A, Hassan C, Romiti A, Giusto M, Guerriero C, Lorenzetti R, et al. Follow-up intestinal metaplasia in the stomach: when, how, and why. World J Gastrointest Oncol. 2012; 4(3):30-6. https://doi.org/10.4251/wjgo.v4.i3.30 PMid:22468181 PMCid:PMC3312926
Lage J, Uedo N, Dinis-Ribeiro M, Yao K. Surveillance of patients with gastric precancerous conditions. Best Pract Res Clin Gastroenterol. 2016; 30(6):913-22. https://doi.org/10.1016/j.bpg.2016.09.004 PMid:27938786
Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006; 12:354-62. https://doi.org/10.3748/wjg.v12.i3.354 PMCid:PMC4066052
Song H, Ekheden IG, Zheng Z, Ericsson J, Nyren O, Ye W. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ. 2015; 351:1-7. https://doi.org/10.1136/bmj.h3867
Almouradi T, Hiatt T, Attar B. Gastric intestinal metaplasia in an underserved population in the USA: prevalence, epidemiologic, and clinical features. Gastroenterol Res Pract. 2013; 2013:856256. https://doi.org/10.1155/2013/856256 PMid:24235966 PMCid:PMC3819766
Zhang XY, Zhang PY, Aboul-Soud MAM. From inflammation to gastric cancer: role of Helicobacter pylori. Oncol Lett. 2017; 13(2): 543-8. https://doi.org/10.3892/ol.2016.5506 PMid:28356927 PMCid:PMC5351277
Yeh LY, Raj M, Hassan S, Aziz SA, Othman NH, Mutum SS, et al. Chronic atrophic antral gastritis and risk of metaplasia and dysplasia in an area with low prevalence of Helicobacter pylori. Indian J Gastroenterol. 2009; 28(2):49-52. https://doi.org/10.1007/s12664-009-0017-0 PMid:19696988
de Vries AC, van Grieken NC, Looman CW, Casparie MK, Vries E, Meijer GA, et al. Gastric cancer risk in patients with premalignant gastric lesions: A Nationwide Cohort Study in the Netherlands. Gastroenterology. 2008; 134(4):945-52. https://doi.org/10.1053/j.gastro.2008.01.071 PMid:18395075
Tahara T, Arisawa T, Shibata T, Nakamura M, Yamashita H, Yoshioka D, et al. Effect of polymorphisms in the 3'-untranslated region (3'-UTR) of VEGF gene on gastric premalignant condition. Anticancer Res. 2009; 29(2):458-90.
Chekhonin VP, Shein SA, Korchagina AA, Gurina OI. VEGF in tumor progression and targeted therapy. Curr Cancer Drug Targets. 2013; 13(4): 423-43. https://doi.org/10.2174/15680096113139990074 PMid:23167597
Feng CW, Wang LD, Jiao LH, Liu B, Zheng S, Xie XJ. Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: correlation with clinical features. BMC Cancer. 2002; 2:8. https://doi.org/10.1186/1471-2407-2-8 PMid:11978184 PMCid:PMC113262
Eng L, Liu G. VEGF pathway polymorphisms as prognostic and pharmacogenetics factors in cancer: a 2013 update. Pharmacogenomics. 2013; 14(13):1659-67. https://doi.org/10.2217/pgs.13.165 PMid:24088136
Eng L, Azad AK, Habbous S, Pang V, Xu W, Maitland-van der Zee AH, et al. Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a systematic review and meta-analysis. Clin Cancer Res. 2012; 18(17):4526–37. https://doi.org/10.1158/1078-0432.CCR-12-1315 PMid:22733538
Guan X, Zhao H, Niu J, Tang D, Ajani JA, Wei Q. The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer. BMC Gastroenterol. 2009; 9:77. https://doi.org/10.1186/1471-230X-9-77 PMid:19835575 PMCid:PMC2771032
Tzanakis N, Gazouli M, Rallis G, Giannopulous G, Papaconstantinou I, Theodoropoulos G, et al. Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival. J Surg Oncol. 2006; 94(7):624-30. https://doi.org/10.1002/jso.20619 PMid:17111394
Chae YS, Kim JG, Sohn SK. Investigation of vascular endothelial growth factor gene polymorphisms and its association with clinicopathologic characteristics in gastric cancer. Oncology. 2006; 71:266-72. https://doi.org/10.1159/000106788 PMid:17671399
Oh SY, Kwon HC, Kim SH, Lee S, Lee JH, Hwang JA, et al. The relationship of Vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer. BMC Cancer. 2013; 13:43. https://doi.org/10.1186/1471-2407-13-43 PMid:23374220 PMCid:PMC3573956
Mansour-Ghanaei F, Sanaei O, Joukar F. Clinical Validation of an Office-Based 14C-UBT (Heliprobe) for H. pylori Diagnosis in Iranian Dyspeptic Patients. Gastroenterol Res Pract. 2011; 2011:930941. https://doi.org/10.1155/2011/930941 PMid:21760778 PMCid:PMC3132501
Rojborwonwitaya J, Vijitjunykul N. Comparison of the accuracy of two commercial rapid urase tests, CLOtest®, and Pronto Dry®, in detecting Helicobacter pylori Infection. Thai J Gastroenterol. 2005; 6(2):55-60.
Wang F, Sun GP, Zou YF, Zhong F, Ma T, Li XQ, et al. Helicobacter pylori infection predicts favorable outcome in patients with gastric cancer. Curr Oncol. 2013; 20(5):e388-95. https://doi.org/10.3747/co.20.1417 PMid:24155636 PMCid:PMC3805408
Tarnawski AS, Chai J, Jones MK. Esophageal and gastrointestinal microcirculation: essential for mucosal protection, a target for injury, and a critical component of injury and ulcer healing. In: Ishii H, Suematsu M, Tanishita K (eds). Organ microcirculation: a gateway to diagnostic and therapeutic intervention. Tokyo: Springer, 2005:49-61. https://doi.org/10.1007/4-431-27174-0_7
Chen J, Li T, Wu Y, He L, Zhang L, Shi T, et al. Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2011; 137(12):1799–812. https://doi.org/10.1007/s00432-011-1057-2 PMid:21918901
Tuccillo C, Cuorno A, Rocco A, Martinelli E, Staibano S, Mascolo M, et al. Vascular endothelial growth factor and neo-angiogenesis in H. pylori gastritis in humans. J Pathol. 2005; 207(3):277–84. https://doi.org/10.1002/path.1844 PMid:16184519
Raica M, Mogoant˘a L, Cimpean AM, Alexa A, Ioanovici S, M˘arg˘aritescu C. Immunohistochemical expression of vascular endothelial growth factor (VEGF) in intestinal type gastric carcinoma. Rom J Morphol Embryol. 2008; 49(1):37-42. PMid:18273500
Corvalan AH, Carrasco G, Saavedra K. The genetic and epigenetic bases of gastritis. In Mozsik G (ed). Current Topics in Gastritis. London: In Tech, 2012:79-95.
Sripichai O, Fucharoen S. Genetic polymorphisms, and implication for human diseases. J Med Assoc Thai. 2007; 90(2):394-8. PMid:17375650
Guan X, Zhao H, Niu J, Tan D, Ajani JA, Wei Q. Polymorphisms of TGFβ1 and VEGF genes and survival of patients with gastric cancer. J Exp Clin Cancer Res. 2009; 28(1):94. https://doi.org/10.1186/1756-9966-28-94 PMid:19566948 PMCid:PMC2717936
Al-Moundhri MS, Al-Nabhani M, Burney IA, Al-Farsi A, Al-Bahrani B. Gastric cancer risk predisposition and prognostic significance of vascular endothelial growth factor (VEGF) gene polymorphisms – a case-control study in an Omani population. Mol Carcinog. 2009; 48(12):1170-6. https://doi.org/10.1002/mc.20572 PMid:19676106
Kim N, Park YS, Cho SI, Lee HS, Choe G, Kim IW, et al. Prevalence and risk factors of atrophic gastritis and intestinal metaplasia in a Korean population without significant gastro-duodenal disease. Helicobacter. 2008;13:245–55. https://doi.org/10.1111/j.1523-5378.2008.00604.x PMid:18665932
den Hoed CM, van Eijck BC, Capelle LG, van Dekken H, Biermann K, Siersema PD, et al. The prevalence of premalignant gastric lesions in asymptomatic patients: predicting the future incidence of gastric cancer. Eur J Cancer. 2011; 47:1211-8. https://doi.org/10.1016/j.ejca.2010.12.012 PMid:21239166
Benberin V, Bektayeva R, Karabayeva R, Lebedev A, Akemeyeva K, Paloheimo L, et al. Prevalence of H. pylori Infection and Atrophic Gastritis Among Symptomatic and Dyspeptic Adults in Kazakhstan. A Hospital based Screening Study Using a Panel of Serum Biomarkers. Anticancer Res. 2013; 33:4595-6. PMid:24123036
Gaol NL, Husin. Dilema pemberantasan minuman keras terhadap pelestarian budaya masyarakat Batak Toba (studi kasus di Desa Ria-Ria Kecamatan Pollung Kabupaten Humbang Hasundutan). Citizenship. 2013; 1:101-21.
Maran S, Lee YY, Xu S, Rajab N, Hasan N, Aziz SH, et al. Gastric precancerous lesions are associated with gene variants in Helicobacter pylori-susceptible ethnic Malays. World J Gastroenterol. 2013; 19:3615-22. https://doi.org/10.3748/wjg.v19.i23.3615 PMid:23801863 PMCid:PMC3691040
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
